IP Verse

Novel Antitumoral Use Of Cabazitaxel - EP2493466

EP2493466

AVENTIS PHARMA
Application Number
EP10782039A
Filing Date
Oct 27, 2010
Status
Opposition Rejected
Sep 19, 2025
Grant Date
Mar 10, 2021
External Links
Slate, Register, Google Patents

Bibliography

The patent EP2493466B1 was granted to Aventis Pharma on Mar 10, 2021 following the initial filing on Oct 27, 2010 under the application number EP10782039A . The current legal status of the patent is Opposition Rejected.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (13)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ACCORD HEALTHCARE SLUAug 30, 2024INTERVENTION ADMISSIBLE
MAIWALDDec 10, 2021ADMISSIBLE
STADA ARZNEIMITTELDec 9, 2021ADMISSIBLE
VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBBDec 3, 2021ADMISSIBLE
GENERICS UKJun 8, 2021ADMISSIBLE
DR REDDYS LABORATORIES BETAPHARM ARZNEIMITTELMar 31, 2021ADMISSIBLE
FRESENIUS KABI DEUTSCHLANDMar 23, 2021ADMISSIBLE
MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATEMar 22, 2021WITHDRAWN
ZENTIVA KSMar 12, 2021ADMISSIBLE
EVER VALINJECTMar 12, 2021WITHDRAWN
ACCORD HEALTHCAREMar 10, 2021ADMISSIBLE
GLENMARK PHARMACEUTICALS EUROPEMar 10, 2021ADMISSIBLE
TEVA PHARMACEUTICALSMar 10, 2021WITHDRAWN

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0817779
DESCRIPTIONUS5847170
DESCRIPTIONWO2005002846
DESCRIPTIONWO9630355
INTERNATIONAL-SEARCH-REPORTEP2177630
INTERNATIONAL-SEARCH-REPORTUS2005065138
OPPOSITIONUS2005065138
OPPOSITIONWO2005028462
OPPOSITIONWO9630355
OTHEREP2493466

Non-Patent Literature (NPL) Citations (78) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Aller A W; Kraus L A; Bissery M C, "Abstract 1923: IN VITRO ACTIVITY OF TXD258 IN CHEMOTHERAPEUTIC RESISTANT TUMOR CELL LINES", Proceedings of the American Association for Cancer Research, (20000000), vol. 41, page 302, XP001525864-
OPPOSITION- Anonymous, "Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer - second line after docetaxel", National Horizon Scanning Centre (NHSC), (20090401), pages 1 - 5, National Horizon Scanning Centre (NHSC), URL: http://www.io.nihr.ac.uk/wp-content/uploads/migrated/1620.57c5f0aea7125ceb4d54424ffb8f2c6b.pdf, (20200817), XP055722792-
OPPOSITION- Anonymous, "Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer - second line after docetaxel", NHSC GUIDANCE DOCUMENT, (20090400), pages 1 - 5, URL: http://www.io.nihr.ac.uk/wp-content/uploads/migrated/1620.57c5f0aea7125ceb4d54424ffb8f2c6b.pdf, XP055722792-
OPPOSITION- Anonymous, "Cabazitaxel XRP-6258 for hormone refractory prostate cancer", NHSC, (20090401), pages 1 - 5, URL: http://www.io.nihr.ac.uk/wp-content/uploads/migrated/1620.57c5f0aea7125ceb4d54424ffb8f2c6b.pdf, XP055722792-
OPPOSITION- Anonymous, "EMEA General Guidance for Clinical Trials; ICH Topic E 8 - General Considerations for Clinical Trials", EMEA General Guidance for Clinical Trials, (19980300), pages 1 - 14, XP002744728-
OPPOSITION- Anonymous, "Guideline on the evaluation of anticancer medicinal products in man", EMA/CHMP/205/95 Rev.5, (20170922), pages 1 - 43, EMA/CHMP/205/95 Rev.5, (20190911), XP055621264-
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION - JEVTANA (cabazitaxel)", JEVTANA, (20100600), pages 1 - 25, XP055770144-
OPPOSITION- Anonymous, "INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE", General Considerations for Clinical Trials E8, (19970717), pages 1 - 17, XP055845138-
OPPOSITION- Anonymous, "JEVTANA® 60 mg Konzentrat und Lösungsmittel zur Herstellung einer Infusionlösung", SANOFI GENZYME Fachinformation, (20170401), XP055617507-
OPPOSITION- Anonymous, "Junta General de Accionistas 2003", Zeltia, (20030101), pages 1 - 61, Zeltia, (20220411), XP055911158-
OPPOSITION- Anonymous, "Novacea, Inc. Announces Preliminary Findings From Data Analysis of Ascent-2 Phase 3 Trial", (20080604), pages 1 - 1, BioSpace , URL: https://www.biospace.com/article/releases/novacea-inc-announces-preliminary-findings-from-data-analysis-of-ascent-2-phase-3-trial-/, (20240207), XP093128779-
OPPOSITION- Anonymous, "Sanofi-aventis provides an R&D Pipeline update", Sanofi Aventis, (20091221), pages 1 - 2, XP055894891-
OPPOSITION- Anonymous, "Sanofi-aventis provides R&D Pipeline update", Sanofi-aventis Press Release, (20091221), pages 1 - 2, XP055874730-
OPPOSITION- Anonymous, "Taxotere SUMMARY OF PRODUCT CHARACTERISTICS", Taxotere, (20081100), pages 1 - 109, XP055912098-
OPPOSITION- Anonymous, "XRP6258 and XRP9881 Novel Taxoids", Aventis Pharmaceuticals, (20030000), pages 1 - 2, XP055845209-
OPPOSITION- Anonymous, "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostatae Cnacer (TROPIC)", ClinicalTrial.gov NCT00417079, (20090911), pages 1 - 4, XP055911510-
OPPOSITION- anonymous, "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer", Protocol of clinical trials NCT00417079, (20081114), URL: https://clinicaltrials.gov/ct2/history/NCT00417079?V_8=View#StudyPageTop, XP055790142-
OPPOSITION- Anonymous, "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)", ClinicalTrials.gov NCT00417079, (20081114), pages 1 - 5, ClinicalTrials.gov NCT00417079, (20220105), XP055876295-
OPPOSITION- Anonymous, "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)", ClinicalTrials.gov NCT00417079, (20081114), pages 1 - 5, ClinicalTrials.gov NCT00417079, URL: https://clinicaltrials.gov/ct2/history/NCT00417079?V_8=View#StudyPageTop, (20220105), XP055876295-
OPPOSITION- anonymous, "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)", Clinicaltrials NCT00417079, (20090911), URL: https://clinicaltrials.gov/ct2/show/NCT00417079, XP055722791-
OPPOSITION- Anonymous, "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)", The clinical study page on clinicaltrials.gov for study NCT00417079, (20090911), The clinical study page on clinicaltrials.gov for study NCT00417079, URL: https://clinicaltrials.gov/ct2/show/NCT00417079, (20200817), XP055722791-
OPPOSITION- Anonymous, "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)", Web Archive, (20090911), pages 1 - 5, XP055722791-
OPPOSITION- ATTARD et al., Pathologie Biologie, (20060000), pages 72 - 84-
OPPOSITION- BARRY MIRTSCHING, "Prostate Cancer clinical trials in Dallas, Texas Area", The Prostate Cancer Blog, (20071110), pages 1 - 3, XP055789938-
OPPOSITION- Bissery Marie-Christine, H, Bouchard, J. F Riou, P. Vrignaud. C. Combeau, J. D Bourzat, A. Commercon. And F. Lavelle , "#1364 PRECLINICAL EVALUATION OF TX0258. A NEW TAXOID", PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS - PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, (20000301), vol. 41, page 214, XP093121720-
OPPOSITION- Cora N Sternberg , Iwona A Skoneczna, Daniel Castellano, Christine Theodore, Normand Blais, Eric Voog, Joaquim Bellmunt, Frank Peters, Solenn Le-Guennec, Linda Cerbone, Marie-Laure Risse, Jean-Pascal Machiels, "Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB)", Oncology, (20130000), vol. 85, no. 4, pages 208 - 215, XP055845187-
OPPOSITION- DR BARRY MIRTSCHING, "Center for Oncology Research & Treatment-Dallas, TX Innovative Cancer Treatment", Blog posts, (20070706), pages 1 - 2, XP055844989-
OPPOSITION- DR BARRY MIRTSCHING, "Prostate Cancer Clinical Trials in Dallas , Texas Area", the Prostate Cancer blog, (20071012), pages 1 - 4, XP055789938-
OPPOSITION- Dr Barry Mirtsching, "Prostate Cancer clinical trials in Dallas, Texas Area", the Prostate Cancer blog, (20071012), the Prostate Cancer blog, URL: https://cancer.healthdiaries.com/, (20210325), XP055789938-
OPPOSITION- DR BARRY MIRTSCHING, "Prostate Cancer clinical trials in Dallas, Texas Area", the Prostate Cancer blog, (20071012), URL: https://cancer.healthdiaries.com/, XP055789938-
OPPOSITION- E Galletti, Magnani M Et Al, "Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes", ChemMedChem, (20070627), vol. 2, pages 920 - 942, XP055710948-
OPPOSITION- E. GALLETTI, "Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes", ChemMedChem, (20070627), vol. 2, pages 920 - 942, XP055710948-
OPPOSITION- Eric Winquist, Mackenzie Mary J, Rodrigues George, "Open clinical uro-oncology trials in Canada", The Canadian Journal of Urology, (20080201), vol. 15, no. 1, pages 3942 - 3949, XP055746783-
OPPOSITION- "Extract related to trial n. NCT00417079", NCT00417079, (20090911), XP055722791-
OPPOSITION- GALLETTI Elena, Magnani M Et Al, "Paclitaxel and Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes", (20070627), vol. 2, no. 7, doi:10.1002/cmdc.200600308, pages 920 - 942, XP055710948-
OPPOSITION- Goetz A. D., Denis L.J., Rowinsky L., Ochoa K., Molpus B., Deblonde D. Et Al., "419. Phase I and Pharmacokinetic Study of RPR116258A, a Novel Taxane Derivative, Administered Intravenously over 1 Hour Every 3 Weeks", CLINICAL PHARMOCOLOGY - PROCEEDINGS OF ASCO, (20010101), vol. 20, page 106a, XP093121715-
OPPOSITION- Information for the patient concerning the clinical study 42446 02 041-
OPPOSITION- JAEHDE, "KLINISCHE PRÜFUNG VON ARZNEIMITTELN", JAEHDE, LEHRBUCH DER KLINISCHEN PHARMAZIE, Stuttgart, (19980000), pages 103 - 114, ISBN 9783804716216, XP055845146-
OPPOSITION- L. Bo, "Un projet de médicament stoppé in extremis", Les Echos, (20091222), URL: https://www.lesechos.fr/2009/12/un-projet-de-medicament-stoppe-in-extremis-470777, XP055789957-
OPPOSITION- Mulcahy Nick, "Phase 3 Trial of Immunotherapy for Metastatic Prostate Cancer Terminated", (20081017), pages 1 - 2, Medscape , URL: https://www.medscape.com/viewarticle/582220_print, (20240207), XP093128784-
OPPOSITION- NHSC, "Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer - second line after docetaxel", Guidance document, (20090401), pages 1 - 5, URL: http://www.io.nihr.ac.uk/wp-content/uploads/migrated/1620.57c5f0aea7125ceb4d54424ffb8f2c6b.pdf, XP055722792-
OPPOSITION- Ramesh K. Ramanathan ; Joel Picus ; Haralambos Raftopoulos ; Stephen Bernard ; A. Craig Lockhart ; Gary Frenette ; John Macdonald ; Susan Melin ; Daniel Berg ; Frank Brescia ; Howard Hochster ; Allen Cohn, "A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer", Cancer Chemotherapy and Pharmacology, Berlin, DE , (20070522), vol. 61, no. 3, doi:10.1007/s00280-007-0489-5, ISSN 1432-0843, pages 453 - 458, XP019561460-
OPPOSITION- Rosenberg J. E., Weinberg Vk, Kelly Wk, Michaelson D, Hussain Mh, Wilding G, Gross M, Hutcheon D, Small Ej, "Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.", Cancer, (20070000), vol. 110, no. 3, pages 556 - 563, XP055845173-
OPPOSITION- Sánchez Catherine, Patricia Mendoza, Héctor R Contreras, Jorge Vergara, James A Mccubrey, Christian Huidobro, Enrique A Castellón, "Expression of Multidrug Resistance Proteins in Prostrate Cancer is Related With Cell Sensitivity to Chemotherapeutic Drugs", Prostate, (20090000), vol. 69, no. 15 September, pages 1448 - 1459, XP055845205-
OPPOSITION- Sanofi, "Sanofi-aventis provides an R&D pipelines updates", Sanofi-aventis Press Release, (20091222), pages 1 - 2, XP055790137-
OPPOSITION- SANOFI, "Sanofi-aventis provides an R&D pipelines updates", SANOFI-AVENTIS PRESS RELEASE, (20091222), pages 1 - 2, XP055790137-
OPPOSITION- Sartor Alton Oliver, "Novel Antitumoral use of Cabazitaxel", DECLARATION OF DR SARTOR, (20201223), pages 1 - 11, XP055894896-
OPPOSITION- Staff Reuters, Viehbacher D , Discover Thomson, Reuters, "Update 1-Sanofi CEO to give mid-term view at end of 2009", Reuters, (20091221), pages 1 - 4, XP055912064-
OPPOSITION- the Prostate Cancer blog, (20071012), XP055789938-
OPPOSITION- "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC", The clinical study page on clinicaltrials.gov for study NCT00417079, (20090911), XP055609984-
OPPOSITION- Ziada Ali, Barqawi Albaha, Glode L. Michael, Varella-Garcia Marileila, Crighton Frances, Majeski Susan, Rosenblum Mark, Kane Madeleine, Chen Lin, Crawford E. David, "The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial", The prostate, US , (20040901), vol. 60, no. 4, doi:10.1002/pros.20065, ISSN 0270-4137, pages 332 - 337, XP093087027
OPPOSITION- S. Oudard, P. Beuzeboc, E. Voog, P. Barthelemy, A. Thiery-Vuillemin, M. Bennamoun, A. Hasbini, K. Aldabbagh, C. Saldana, E. Sevin, Y.E. Amela, G. Von Amsberg, N. Houede, D. Besson, S. Feyerabend, M. Boegemann, D. Pfister, M. Schostak, O. Huillard, C. Helissey, "Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial", Annals of Oncology , (20220101), vol. 33, no. S7, doi:10.1016/j.annonc.2022.07.1495, pages S1164 - S1165, XP093128775
OPPOSITION- Attard G et al, "Update on tubulin-binding agents", Pathologie Biologie, L'EXPANSION SCIENTIFIQUE FRANCAISE, PARIS., FR, FR , (20060301), vol. 54, no. 2, doi:10.1016/j.patbio.2005.03.003, ISSN 0369-8114, pages 72 - 84, XP024926230
OPPOSITION- ATTARD G., Greystoke G; Kaye A; De Bono S; J, "Update on tubulin-binding agents", PATHOLOGIE ET BIOLOGIE, (20060301), vol. 54, no. 2, doi:10.1016/j.patbio.2005.03.003, pages 72 - 84, XP005336495
OPPOSITION- SARTOR, O., "Endpoints in prostate cancer clinical trials", Urology, (20020000), vol. 60, pages 101 - 108, XP055912110
OPPOSITION- Sartor Oliver, Weinberger Maribeth, Moore Andrea, Li Ailing, Figg William D, "Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer", UROLOGY., BELLE MEAD, NJ, US, US , (19980801), vol. 52, no. 2, doi:10.1016/S0090-4295(98)00149-6, ISSN 0090-4295, pages 252 - 256, XP055797370
OPPOSITION- de Bono, J.S. et al, "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20101002), vol. 376, no. 9747, doi:10.1016/S0140-6736(10)61389-X, ISSN 0140-6736, pages 1147 - 1154, XP027373072
OPPOSITION- de Bono, J.S. ; Oudard, S. ; Ozguroglu, M. ; Hansen, S. ; Machiels, J.P. ; Kocak, I. ; Gravis, G. ; Bodrogi, I. ; Mackenzie, M.J. ; Shen, L. ; Roessner, M. ; Gupta, S. ; Sartor, A.O., "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20101002), vol. 376, no. 9747, doi:10.1016/S0140-6736(10)61389-X, ISSN 0140-6736, pages 1147 - 1154, XP027373072
OPPOSITION- J.-S. DE BONO et al., "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial", Lancet, (20100000), vol. 376, no. 9747, pages 1147 - 1154, XP027598276
OPPOSITION- TANNOCK IAN F et al, "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.", New England Journal of Medicine, The - NEJM, Massachusetts Medical Society, US, US , (20041007), vol. 351, no. 15, doi:10.1056/NEJMoa040720, ISSN 1533-4406, pages 1502 - 1512, XP002623317
OPPOSITION- TANNOCK IAN F; WIT DE RONALD; BERRY WILLIAM R; ET AL, "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer", N Engl J Med, (20040000), vol. 351, no. 15, pages 1502 - 1512, XP002623317
OPPOSITION- TANNOCK IAN F , WIT DE RONALD, BERRY WILLIAM R, ET AL, "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.", New England Journal of Medicine, The - NEJM, Massachusetts Medical Society, US, US , (20041007), vol. 351, no. 15, doi:10.1056/NEJMoa040720, ISSN 1533-4406, pages 1502 - 1512, XP002623317
OPPOSITION- Pivot X, et al, "A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients.", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO SEP 2008, (20080901), vol. 19, no. 9, doi:10.1093/annonc/mdn171, pages 1547 - 1552, XP002551475
OPPOSITION- Pivot X., P Koralewski, J L Hidalgo, A Chan, A Gonçalves, G Schwartsmann, S Assadourian, J P Lotz, "A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients", Annals of Oncology, (20080000), vol. 19, pages 1547 - 1552, XP002551475
OPPOSITION- X. PIVOT, Koralewski P; Hidalgo J L; Chan A; Gonçalves A; Schwartsmann G; Assadourian S; Lotz J P, "A multicentre phase II study of XRP6258 administered as 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients", ANNALS OF ONCOLOGY, (20080901), vol. 19, no. 9, doi:10.1093/annonc/mdn171, pages 1547 - 1552, XP002551475
OPPOSITION- Beardsley Emma K; Chi Kim N, "Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.", Current opinion in supportive and palliative care, Wolters Kluwer Health Lippincott Williams & Wilkins, (20080901), vol. 2, no. 3, doi:10.1097/SPC.0b013e32830c48a3, ISSN 1751-4266, pages 161 - 166, XP009149037
OPPOSITION- Beardsley Emma K; Chi Kim N, "Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer", Curr Op Suppor Palliat Care, (20080000), vol. 2, no. 3, pages 161 - 166, XP009149037
OPPOSITION- E.K. BEARDSLEY, "Systemic therapy after firsMine docetaxel in metastatic castration-resistant prostate cancer", Curr. Op. Support. Palliat. Care, (20080901), vol. 2, no. 3, pages 161 - 166, XP009149037
OPPOSITION- Eric J. Small; Joseph Fontana; Nizar Tannir; Robert S. DiPaola; George Wilding; Mark Rubin; Renee Bailey Iacona; Fairooz F. Kabbinavar, "A phase II trial of gefitinib in patients with non‐metastatic hormone‐refractory prostate cancer", BJU International, Hoboken, USA, (20070903), vol. 100, no. 4, doi:10.1111/j.1464-410X.2007.07121.x, ISSN 1464-4096, pages 765 - 769, XP072220668
OPPOSITION- A.C. MITA et al., "Phase I and Pharmacokinetic Study of XRP6258 (RPR116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors", Clin . Cancer Res., (20090000), vol. 15, doi:10.1158/1078-0432.ccr-08-0596, pages 723 - 730, XP002623316
OPPOSITION- A.C. MITA, "Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors", Clin. Cancer Res., (20090115), vol. 15, no. 2, pages 723 - 730, XP002623316
OPPOSITION- Alain C. Mita et al, "Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors", Clinical Cancer Research, Association for Cancer Research, US, US, (20090115), vol. 15, no. 2, doi:10.1158/1078-0432.ccr-08-0596, ISSN 1078-0432, pages 723 - 730, XP002623316
OPPOSITION- Alain C. Mita, Louis J. Denis, Eric K. Rowinsky, Johann S. DeBono, Andrew D. Goetz, Leonel Ochoa, Bahram Forouzesh, Muralidhar Beeram, Amita Patnaik, Kathleen Molpus, Dorothée Semiond, Michèle Besenval and Anthony W. Tolcher, "Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors", Clinical Cancer Research, Association for Cancer Research, US, US, (20090115), vol. 15, no. 2, doi:10.1158/1078-0432.ccr-08-0596, ISSN 1078-0432, pages 723 - 730, XP002623316
OPPOSITION- A. MITA et al., "Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumours", Clinical Cancer Research, (20090115), vol. 15, no. 2, doi:10.1158/1078-0432.ccr-08-0596, pages 723 - 730, XP002623316
OPPOSITION- MITA A. C. et al., "Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors", Clin Cancer Res, (20090115), vol. 15, no. 2, pages 723 - 730, XP002623316
OPPOSITION- MITA et al., "Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors", Clin Cancer Res, (20090000), vol. 15, no. 2, pages 723 - 730, XP002623316
OPPOSITION- MITA et al., "Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors", Clin Cancer Res, (20090115), vol. 15, no. 2, doi:10.1158/1078-0432.ccr-08-0596, pages 723 - 30, XP002623316
OPPOSITION- Sumanta Kumar Pal, Przemyslaw Twardowski, and Oliver Sartor, "Critical appraisal of cabazitaxel in the management of advanced prostate cancer", Clinical Interventions in Aging, (20101203), vol. 5, doi:10.2147/CIA.S14570, pages 395 - 402, XP009144702

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents